Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Phase 4

Completed

Conditions: Angina Pectoris
Type 2 Diabetes Mellitus
Coronary Artery Disease

Interventions: Drug: Ranolazine placebo
Drug: Ranolazine

Registration Number: NCT01425359

Lead Sponsor: Gilead Sciences

Brief Summary: This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day. Ranolazine is approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.

Detailed Description: Participants who meet the eligibility criteria at screening will enter a 4-to 6-week Qualifying Period. The allowed concomitant antianginal medication(s) must be maintained at a stable dose throughout the study. Participants will document the number of angina episodes, number of sublingual nitroglycerin doses taken, and a dyspnea score (on a scale from 1 to 5) on a daily basis in a diary. Participants eligible to stay in the study after the Qualifying Period will enter the 8-week double-blind dosing phase. Participants will have study visits at the end of Weeks 2 and 8. Participants will continue to document the number of angina episodes and number of sublingual nitroglycerin doses taken as well as a dyspnea score on a daily basis by the end of each day in their diary. In addition, participants will be called during Week 2 and at the end of Week 5 to encourage compliance. A safety follow-up phone call will be made 14 days after the last study visit or early discontinuation.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 949

Inclusion Criteria

Written informed consent
Males and females aged at least 18 years
At least a 3-month history of chronic stable angina triggered by physical effort and relieved by rest and/or sublingual nitroglycerin
CAD documented by one or more of the following:
1. Angiographic evidence of ≥ 50% stenosis of one or more major coronary arteries
2. History of myocardial infarction (MI) documented by positive myocardial muscle creatine kinase (CK-MB) enzymes, troponins, or electrocardiogram (ECG) changes
3. Cardiac imaging study or exercise test diagnostic for CAD
Treatment with up to 2 antianginal therapies at a stable dose for at least 2 weeks prior to the Qualifying Period.
Documented history of T2DM
Willing to maintain stable tobacco usage habits throughout the study
Willing to maintain stable activity levels throughout the study
Females of childbearing potential must agree to utilize highly effective contraception methods from Screening throughout the duration of study treatment and for 14 days following the last dose of study drug.

Exclusion Criteria

New York Heart Association (NYHA) Class III and IV
Acute coronary syndrome in the prior 2 months or planned coronary revascularization during the study period
Stroke or transient ischemic attack within 6 months prior to Screening
QTc > 500 milliseconds
Uncontrolled hypertension (seated systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg)
Systolic blood pressure < 100 mmHg
Clinically significant hepatic impairment
Prior treatment with ranolazine, or known hypersensitivity or intolerance to ranolazine
Females who are breastfeeding
Positive serum pregnancy test
Participation in another investigational drug or device study within 1 month prior to Screening
Current treatment with trimetazidine, ivabradine, or nicorandil. Subjects will need to discontinue these medications 2 weeks prior to the Qualifying Period.
Current treatment with potent inhibitors of cytochrome (CYP)3A (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)
Current treatment with CYP3A and P glycoprotein (Pgp) inducers (eg, rifampicin/rifampin, carbamazepine, and St. John's wort [Hypericum perforatum])
Current treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine, tacrolimus, and sirolimus)
Subjects taking simvastatin who cannot reduce the dose to 20 mg once daily or who cannot switch to another statin
Current treatment with Class I or III antiarrhythmic medications
History of illicit drug use or alcohol abuse within 1 year of Screening
Any other conditions that, in the opinion of the investigator, are likely to prevent compliance with the study protocol or pose a safety concern if the subject participates in the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Ranolazine placebo	Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks.
Ranolazine	Ranolazine placebo	Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks.
Ranolazine	Ranolazine	Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks.

Primary Outcome Measures

Name	Time	Method
Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment	6 weeks	Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks. For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores	Up to 8 weeks	The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey.
Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment	6 weeks	Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment.
Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency	6 weeks
Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency	6 weeks	For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined.
Patient's Global Impression of Change (PGIC) Scale Score	8 weeks	The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved).

Trial Locations

Locations (131): Cardiology and Medicine Clinic
🇺🇸
Little Rock, Arkansas, United States
Merced Heart Associates
🇺🇸
Merced, California, United States
Spectrum Clinical Research Institute, Inc
🇺🇸
Moreno Valley, California, United States
Sacramento Heart and Vascular Research Center
🇺🇸
Sacramento, California, United States
South Florida Research Solutions, LLC
🇺🇸
Hollywood, Florida, United States
Baptist Heart Specialist
🇺🇸
Jacksonville, Florida, United States
Clinical Research of Central Florida
🇺🇸
Winter Haven, Florida, United States
Masters of Clinical Research, Inc.
🇺🇸
Augusta, Georgia, United States
Columbus Cardiology Associates
🇺🇸
Columbus, Georgia, United States
Central Cardiology Associates
🇺🇸
Elizabethtown, Kentucky, United States
Scroll for more (121 remaining)
Cardiology and Medicine Clinic
🇺🇸Little Rock, Arkansas, United States